Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q2 2025 Earnings Presentation
24 slides from Indivior Pharmaceuticals's earnings presentation, Jul 31, 2025
Slide 1: Q2 2025 Results
Z) < INDIVIOR Q2 2025 Results July 31, 2025
Slide 2: Important Cautionary Statement Regarding Forward-looking Statements
Q2 2025 RESULTS | JULY 31, 2025 Important Cautionary Statement Regarding Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: the Company’s financial guidan
Slide 3: Joe Ciaffoni, Chief Executive Officer
Joe Ciaffoni Chief Executive Officer
Slide 4: Call Agenda
Q2 2025 RESULTS | JULY 31, 2025 Call Agenda Overview & Indivior Action Agenda Joe Ciaffoni, CEO SUBLOCADE® Commercial Strategy Patrick Barry, CCO Q2 Performance & FY 2025 Guidance Ryan Preblick, CFO Conclusion Joe Ciaffoni, CEO Q&A All participants 4
Slide 5: Pioneering life-transforming treatment for opioid use disorder
Pioneering life-transforming treatment for opioid use disorder to make meaningful recovery possible
Slide 6: Q2 2025 Business Highlights
Q2 2025 RESULTS | JULY 31, 2025 Q2 2025 Business Highlights Total SUBLOCADE Adjusted Net Revenue Net Revenue EBITDA1 +1% +9% (5)% $299m $302m $209m $93m $88m $192m Q2'24 Q2'25 Q2'24 Q2'25 Q2'24 Q2'25 Raising Full-Year 2025 Financial Guidance 1Adjusted EBITDA is a Non-GAAP Financial Measure with Net
Slide 7: FY 2025: A Transition Year
Q2 2025 RESULTS | JULY 31, 2025 FY 2025: A Transition Year Foundational Leadership Additions Strengthening expertise and leadership at the Board and Executive levels Daniel Dr. David Joe Ninivaggi Wheadon Ciaffoni Independent Non- BOD Chair Chief Executive Officer Executive Director Tony Vanessa Kin
Slide 8: Indivior Action Agenda
Q2 2025 RESULTS | JULY 31, 2025 Indivior Action Agenda Phase I (Generate Momentum) Underway Phase III – Breakout (H2’26 – Beyond) • Leverage strengthened financial profile to acquire next growth drivers Phase II – Accelerate (Jan. ’26) • Accelerate U.S. SUBLOCADE net revenue • Generate immediate acc
Slide 9: Patrick Barry, Chief Commercial Officer
Patrick Barry Chief Commercial Officer
Slide 10: U.S. SUBLOCADE Performance
Q2 2025 RESULTS | JULY 31, 2025 Q2 2025 U.S. SUBLOCADE Performance Strong SUBLOCADE Dispense Growth1 TTM SUBLOCADE Patients2 +6% +7% YoY YoY +9% QoQ 171,519 160,365 165,700 155,700 151,900 // Q2'24 Q2'25 Q2'24 Q1'25 Q2'25 Growing SUBLOCADE Prescriber Base3 Improving Prescriber Depth: HCPs with 5+ SU
Slide 11: Improving U.S. SUBLOCADE Commercial Execution to Generate Momentum
Q2 2025 RESULTS | JULY 31, 2025 Improving U.S. SUBLOCADE Commercial Execution to Generate Momentum OVERRIDING GOAL: Extend SUBLOCADE’s Position as No. 1 LAI Choice Field Force Execution: Payor Pull-Through: Specialty Pharmacy HCP and Patient Media: Performance: • Improving field force • Leveraging b
Slide 12: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 13: Q2 2025 Financial Highlights
Q2 2025 RESULTS | JULY 31, 2025 Q2 2025 Financial Highlights OPERATING RESULTS: KEY TAKEAWAYS: (vs. Q2 2024 unless otherwise indicated) $ mil Q2 2025 Q2 2024 Change Total Net Revenue up 1% with SUBLOCADE Net Revenue offsetting Net Revenue (NR): 302 299 1% SUBOXONE Film Net Revenue erosion and PERSER
Slide 14: Cash and Borrowing Position
Q2 2025 RESULTS | JULY 31, 2025 Cash and Borrowing Position CASH AND BORROWING KEY TAKEAWAYS: (vs. December 31, 2024, unless otherwise indicated) $ mil June 30, 2025 Dec 31, 2024 Cash & Investments of $538m1 Cash & Cash Equivalents 510 319 • Strong YTD cash generated by operations ST and LT Investme
Slide 15: 2025 Financial Guidance Reconciliation: Introducing Adjusted EBITDA
Q2 2025 RESULTS | JULY 31, 2025 2025 Financial Guidance Reconciliation: Introducing Adjusted EBITDA1 Non-GAAP Operating Expenses $610m-$625m -$25m $585m-$600m 4/24/25 Non-GAAP Operating Exclude Expected Stock- based Compensation Expense Guidance Reconciled • To align with adjusted EBITDA method, exc
Slide 16: Raising 2025 Financial Guidance: Reflecting Stronger Top-line Growth
Q2 2025 RESULTS | JULY 31, 2025 Raising 2025 Financial Guidance: Reflecting Stronger Top-line Growth Previous Guidance Updated Guidance Commentary on Performance-Based Changes to Guidance (4/24/25) (7/31/25)1 (Reconciled for Adjusted EBITDA) • Reflects solid YTD U.S. SUBLOCADE performance and U.S. p
Slide 17: Concluding Remarks
Concluding Remarks
Slide 18: Clear Focus on Executing the Action Agenda and Delivering on Commitments
Q2 2025 RESULTS | JULY 31, 2025 Clear Focus on Executing the Action Agenda and Delivering on Commitments Execute Phase I of Deliver on Raised 2025 Indivior Action Agenda Financial Guidance 18
Slide 19: Years of Indivior
YEARS OF ae INDIVIOR
Slide 20: Appendix
Z) < INDIVIOR Appendix
Slide 21: Key Ongoing Clinical Trials
Q2 2025 RESULTS | JULY 31, 2025 Key Ongoing Clinical Trials Trial Population Patients Design Primary Endpoints Status Estimated Completion INDV-6001 Moderate to Evaluate PK, safety and 3-month long- acting severe Opioid Multiple dose tolerability of INDV-6001 Last Patient First Last Patient Last Vis
Slide 22: Financial Reconciliations
Q2 2025 RESULTS | JULY 31, 2025 Financial Reconciliations Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 GAAP gross profit $ 250 $ 220 $ 472 $ 466 Adjustments within cost of sales Manufacturing transition 2 — 2 — Discontinuation of PERSERIS marketing and promotion — 32 — 3
Slide 23: Financial Reconciliations
Q2 2025 RESULTS | JULY 31, 2025 Financial Reconciliations Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 GAAP research and development expenses $ 21 $ 26 $ 43 $ 54 Adjustments within R&D — — — — Less: Adjustments in research and development expenses — — — — Non-GAAP resear
Slide 24: Financial Reconciliations
Q2 2025 RESULTS | JULY 31, 2025 Financial Reconciliations Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net income (loss) $ 18 $ (97) $ 65 $ (36) Interest income (6) (6) (10) (13) Interest expense 15 9 27 18 Income tax expense (benefit) 44 (23) 56 (12) Depreciation and am
Indivior Pharmaceuticals — Q2 2025 Earnings Presentation on 6ix